BioSpace.com News

Amarin Corporation PLC Announces Notification of Patent Allowance for U.S. Application 13/417,899 Related to Combination Product of Vascepa® and Statin Therapy

Wed, 22 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BEDMINSTER, N.J., and DUBLIN, Ireland, May 22, 2013 (GLOBE NEWSWIRE) -- Amarin Corporation plc (Nasdaq:AMRN), a biopharmaceutical company focused on the commercialization and development of therapeutics to improve...

New Japanese Protozoal Patent for BioDiem Ltd.'s BDM-I

Wed, 22 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Melbourne, 22 May 2013: Australian infectious disease therapy and vaccine development company BioDiem Ltd (ASX: BDM) has today announced the allowance of another Japanese patent for its novel antimicrobial compound...

European and U.S. Cellulase Patents Granted to DIREVO Industrial Biotechnology GmbH

Tue, 21 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Cologne, Germany, May 21, 2013. Direvo Industrial Biotechnology GmbH (Direvo), an expert in enzyme development and optimization from Cologne, announced today the granting of U.S. and European Patents covering...

Acorda Therapeutics Announces Issuance of Additional U.S. Patent for AMPYRA® Covering a Range of Dosage Strengths

Mon, 20 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (Nasdaq: ACOR) today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent Application No. 8,440,703 (the 7...

NeoStem, Inc. Announces Geographic Expansion of Intellectual Property Coverage of Cardiovascular Asset AMR-001

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 16, 2013 (GLOBE NEWSWIRE) -- NeoStem, Inc. (NYSE MKT:NBS) ("NeoStem" or the "Company"), a leader in the emerging cellular therapy market, today announced the geographic expansion of intellectual...

MultiCell Technologies Inc. Files U.S. Patent Application for Targeted Delivery of Noncoding Micro RNAs for the Treatment of Liver Cancer

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

WOONSOCKET, R.I., May 16, 2013 /PRNewswire/ -- MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB) is pleased...

Cellectis: TAL-effector Nuclease: Issuance by the USPTO of Two New Patents

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW BRIGHTON, Minn.--(BUSINESS WIRE)--Regulatory News: Cellectis (Paris:ALCLS) (NYSE PA: ALCLS), the global genome engineering specialist, announced the issuance by the USPTO on May 14th, 2013 of two new US...

Multi-Party and Cross-Border Patent Issues Affecting Biotech Businesses

Thu, 16 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

May 16, 2013 -- Matthew C. Nielsen, Partner at Marshall, Gerstein & Borun LLP, will moderate a panel at the 2013 BIO International Convention titled, Multi-Party and Cross-Border Patent Issues Affecting Biotech...

Nuvo Research Inc. Granted U.S. Patent for Treatment of Allergic Rhinitis and Allergic Asthma With WF10

Wed, 15 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MISSISSAUGA, ON, May 14, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI) a specialty pharmaceutical company dedicated...

Cleveland Biolabs Inc. and Announce US and European Patent Allowances for Curaxins

Tue, 14 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

BUFFALO, N.Y., May 14, 2013 (GLOBE NEWSWIRE) -- Cleveland BioLabs, Inc. (Nasdaq:CBLI) and Incuron, LLC, a joint venture between the Company and Bioprocess Capital Ventures, today announced the receipt of a Notice...

Aegis Therapeutics, LLC Awarded 2nd Patent for Fast Acting Migraine Nasal Spray Treatment

Tue, 14 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 14, 2013 /PRNewswire-iReach/ -- ...

Biotage AB and Peptide Synthesis

Mon, 13 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Uppsala, Sweden, May 13, 2013 / B3C newswire / - CEM Corporation, a competitor of Biotage (STO: BIOT), recently published a press release claiming to have won a patent dispute with Biotage. The so called ...

NuPathe Inc. Announces Allowance of Additional U.S. Patent Application for NP201

Mon, 13 May 2013 12:00:00 AM GMT

CONSHOHOCKEN, PA--(Marketwired - May 13, 2013) - NuPathe Inc. (NASDAQ: PATH) today announced that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U...

Trius Therapeutics Announces Notice of Allowance of U.S. Patent Application Related to Tedizolid Phosphate Combination With Daptomycin

Mon, 13 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

SAN DIEGO, May 13, 2013 (GLOBE NEWSWIRE) -- Trius Therapeutics, Inc. (Nasdaq:TSRX), a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for serious...

Actinium Pharmaceuticals, Inc. Receives Notice of Patent Allowance for a Key Application

Mon, 13 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK, May 13, 2013 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (OTCBB: ATNM), a biopharmaceutical company that...

Suven Life Sciences Ltd Secures Three Product Patents for Their NCEs in Canada and Eurasia

Fri, 10 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HYDERABAD, INDIA (May 10,2013) Suven Life Sciences Ltd (Suven) announces today that the grant of two product patents from Canada (2672190 and 2703157) and one (1) product patent from Eurasia (17154) corresponding...

Nuvo Research Inc. Announces Notice of Intention to Grant a European Patent for PENNSAID® 2%

Thu, 09 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MISSISSAUGA, ON, May 9, 2013 /PRNewswire/ - Nuvo Research Inc. (TSX: NRI), a specialty pharmaceutical...

CEM Corporation Wins Peptide Patent Dispute With Biotage AB

Thu, 09 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MATTHEWS, N.C., May 9, 2013 /PRNewswire/ -- CEM Corporation, a leading global provider of microwave laboratory...

Immunomedics, Inc. Announces Three New Patent Awards

Tue, 07 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MORRIS PLAINS, N.J., May 7, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted...

Provitro Biosciences Awarded First-Ever U.S. Patent for Large-Scale Production of Bamboo Plants

Tue, 07 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MT. VERNON, Wash., May 7, 2013 /PRNewswire/ -- Provitro Biosciences LLC (or "Provitro"), a subsidiary...

Arrowhead Research Corporation Receives Patent Allowance for DPC siRNA Delivery System With Peptide Backbone

Tue, 07 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Research Corporation (NASDAQ:ARWR), a targeted therapeutics company, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark...

Novartis AG Sees Boost From Program Designed to Speed Life-Saving Therapies

Mon, 06 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Just as Novartis AG (NOVN)s best-selling medicines are losing patent protection, the company is poised to get a revenue boost from a U.S. program designed to speed life- saving therapies to patients with...

GE Global Research Researcher Receives 200th U.S. Patent

Mon, 06 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NISKAYUNA, N.Y.--(BUSINESS WIRE)--GE Global Research, the technology development arm of the General Electric Co. (NYSE: GE) is honored to announce that Dr. E. Trifon Laskaris, Chief Engineer and pioneer in imaging...

Patent Issued in China for EntreMed, Inc.'s Lead Drug Candidate ENMD-2076

Mon, 06 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., May 6, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing...

Mapi Pharma Granted United States Patent Covering Glatiramer Depot for Multiple Sclerosis

Mon, 06 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NESS ZIONA, Israel, May 6, 2013 -- /PRNewswire/ --

Mapi Pharma Ltd. (Mapi), developer of complex bulk Active Pharmaceutical Ingredients (APIs), generic and innovative intermediates, and finished...

Patent Issued in U.S. for EntreMed, Inc.'s 2ME2 in Rheumatoid Diseases

Fri, 03 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., May 3, 2013 /PRNewswire/ -- EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company...

Palatin Technologies Announces Notification of Patent Allowance on Melanocortin Receptor-Specific Peptides for Sexual Dysfunction

Thu, 02 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CRANBURY, N.J., May 2, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company...

mPhase Technologies, Inc. Receives Issue Notification of Key Patent

Thu, 02 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LITTLE FALLS, New Jersey, May 2, 2013 /PRNewswire/ --

mPhase Technologies, Inc. (OTCBB: XDSL) reported today that it has received an Issue Notification from the U.S. Patent & Trademark Office for...

Microbix Biosystems Inc. to Receive New LumiSort® Patent in U.S.

Wed, 01 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

TORONTO, May 1, 2013 /CNW/ - Microbix Biosystems Inc. (TSX:MBX), a biotechnology company developing innovative biological products and technologies including LumiSort, a novel sperm sexing technology for the...

USPTO Notice of Allowance Marks Major Achievement for Protelica's Series of VEGFR-2 Antibody Mimics

Wed, 01 May 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for free job search tips!

HAYWARD, Calif., May 1, 2013 (GLOBE NEWSWIRE) -- Crowning almost eight years of research and development Protelica, Inc., an innovator in the field of protein engineering, just received a notice...

Imugene Limited Granted Chinese Patent for Novel Drug Delivery Technology

Tue, 30 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Melbourne, 30 April 2013: Australian drug delivery technology company Imugene (ASX.IMU) has announced today the acceptance of a key Chinese patent application for the Companys novel drug delivery technology...

Teva Pharmaceutical Industries Limited Welcomes Landmark "Victory for Patient" in Intellectual Property Case

Tue, 30 Apr 2013 12:00:00 AM GMT

LONDON, 30 April 2013 - Teva UK Limited (Teva) has welcomed the judgment of the Court of Appeal today in support of its case against AstraZeneca relating to the validity of the patent covering quetiapine ER (a generic version of Seroquel). This ruling confirmed the decision of the UK High Court in March 2012 that AstraZenecas patent was invalid.

Seroquel, an antipsychotic treatment, was...

Catabasis Pharmaceuticals, Inc. Announces Issuance of Patents for CAT-1000 and CAT-2000 Series

Tue, 30 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass., April 30, 2013 /PRNewswire/ -- Catabasis Pharmaceuticals Inc., announced...

Absorption Pharmaceuticals to Receive Patent for Premature Ejaculation Topical Medication

Mon, 29 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

HUNTINGTON BEACH, Calif., April 29, 2013 /PRNewswire/ -- Absorption Pharmaceuticals announced today that the U.S. Patent...

Islet Sciences Receives Japanese Patent Covering New Medications for Diabetes

Mon, 29 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NEW YORK--(BUSINESS WIRE)--Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced...

NuPathe Inc. Announces Allowance of U.S. Patent Application for NP201

Thu, 25 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

CONSHOHOCKEN, PA--(Marketwired - April 25, 2013) - NuPathe Inc.<...

Elite Pharmaceuticals, Inc. Awarded Second U.S. Patent for Abuse Resistant Drug Formulation

Tue, 23 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

NORTHVALE, N.J., April 23, 2013 (GLOBE NEWSWIRE) -- Elite Pharmaceuticals, Inc. ("Elite" or the "Company") (OTCBB:ELTP) today announced the issuance of U.S. Patent No. 8,425,933 entitled "Abuse-Resistant Oral...

Innovus Pharma Announces Allowance of Patent in Europe for Its J. Regia Product

Tue, 23 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

LA JOLLA, Calif., April 23, 2013 (GLOBE NEWSWIRE) -- Innovus Pharmaceuticals, Inc., ("Innovus Pharma") www.innovuspharma.com (OTCBB:INNV) today announced that the European Patent Office ("EPO") has issued...

GW Pharmaceuticals Announces U.S. Patent Allowance for SATIVEX® Formulation Spray Device

Mon, 22 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Porton Down, UK; 22 April 2013: GW Pharmaceuticals plc (AIM: GWP), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid...

ARTES Biotechnology Issued New Patent in Australia for VLP Technology

Mon, 22 Apr 2013 12:00:00 AM GMT

Langenfeld, April 19th, 2013. ARTES Biotechnology specialized in microbial cell line and process development as well as in technology transfer for pharmaceutical industry is pleased to announce the issuance of a new patent for their VLP platform. The patent will further strengthen the Metavax platform of the company. In combination with the expression platform Hansenula Metavax is a unique tool for...

Fuisz Pharma Announces Intent to Divest Strategic Patent for Detection of Opioid Abuse; Seeks Offers for Patent Through May 2013

Mon, 22 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MIAMI, April 22, 2013 /PRNewswire-USNewswire/ -- Fuisz Pharma today announced its intent to divest its strategic...

Addex Therapeutics Announces Issuance of a Broad European Composition of Matter Patent for Dipraglurant

Mon, 22 Apr 2013 12:00:00 AM GMT

GENEVA--(Marketwired - April 22, 2013) - Addex Therapeutics /Addex Announces Issuance of a Broad European Composition of Matter PatentforDipraglurant. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Dipraglurant, an mGlu5 negative allosteric modulator, in clinicaldevelopmentfor...

Medgenics, Inc. Receives Notice of Allowance From the U.S. Patent Office for Claims That Expand IP for Its Platform Technology to Additional Therapeutic Proteins

Mon, 22 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

MISGAV, Israel & SAN FRANCISCO--(BUSINESS WIRE)--Medgenics, Inc. (NYSE Amex: MDGN and AIM: MEDU, MEDG) (the Company), the developer of Biopump, a novel technology for the sustained production and delivery...

Adamas Pharmaceuticals Announces Issuance of First U.S. Patent for Nurelin™ (Amantadine HCl Extended Release) Program

Mon, 22 Apr 2013 12:00:00 AM GMT

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

EMERYVILLE, Calif., April 22, 2013 /PRNewswire/ -- Adamas Pharmaceuticals, Inc. announced today that the United States...

Santaris Pharma A/S Release: Appeal Board Decides in Favor of the Wengel LNA Patent

Thu, 18 Apr 2013 12:00:00 AM GMT

HOERSHOLM, Denmark and SAN DIEGO, April 18, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the EPO has issued Minutes of the Oral Proceedings specifying the Board of Appeal's decision...

Starpharma Holdings Ltd Granted New Drug Delivery Patents

Wed, 17 Apr 2013 12:00:00 AM GMT

Melbourne Australia; 17 April 2013 - Starpharma Holdings Ltd (ASX: SPL; OTCQX:SPHRY) today announced it has been granted three new patents by the United StatesPatent and Trademark Office (USPTO) which strengthen and expand the Companys patentestate for its drug delivery platform.

The patents provide composition of matter protection for Starpharmas dendrimertechnologies for drug...

Suven Life Sciences Ltd Secures 4 Product Patents for Their NCEs in China, Mexico and New Zealand

Wed, 17 Apr 2013 12:00:00 AM GMT

HYDERABAD, INDIA (Apr 17, 2013) Suven Life Sciences Ltd (Suven) announces today that the grant of two (2) product patents from China (ZL 20088001440 and ZL 200880112735) one (1) product patent from Mexico (301421) and one (1) from New Zealand (591833) corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid...

Prima Biomed Awarded Japanese Patent for CVac™

Wed, 17 Apr 2013 12:00:00 AM GMT

SYDNEY, AUSTRALIA--(Marketwired - April 17, 2013) - Prima BioMed Ltd (ASX: PRR) (NASDAQ: PBMD) (ISIN: US74154B2034) ("Prima", "the Company") is pleased to announce that it has been granted a patent from the Japanese Patent Office that protects methods used in the manufacture of CVac. The method of use claims...

Celsus Therapeutics Announces Notification of Patents Granted

Wed, 17 Apr 2013 12:00:00 AM GMT

NEW YORK, NY and LONDON--(Marketwired - April 17, 2013) - Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced today that the United States Patent and Trademark Office (USPTO) has granted patents with claims covering Composition of Matter and Method of Treatments...

Mayo Clinic Issued Patent Covering Personalized Psychiatric Medicine Technology Commercialized by AssureRx

Tue, 16 Apr 2013 12:00:00 AM GMT

MASON, Ohio and ROCHESTER, Minn., April 16, 2013 /PRNewswire/ -- Mayo Clinic and AssureRx Health, Inc. today announced that the United States Patent and Trademark Office (USPTO) issued U.S. Patent No. 8,401,801 encompassing "Methods for Selecting Medications" by Mayo inventors Drs. David...

Antares Pharma, Inc. Announces the Issuance of a New Patent on VIBEX™ Device Platform

Tue, 16 Apr 2013 12:00:00 AM GMT

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced the issuance of U.S. Patent number 8,419,686 which relates to the device-injection site contacting interface. The interface design is applicable to the entire Antares VIBEX injector device platform. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, This is another example of the importance of our...

Veritas Bio's RNA Delivery Patent Allowed by USPTO

Tue, 16 Apr 2013 12:00:00 AM GMT

JUPITER, Fla.--(BUSINESS WIRE)--Veritas Bio, LLC, a privately held biotechnology company is pleased to announce that it has received a Notice of Allowance from the USPTO for Patent Application No. 12/514,237, In Vivo Delivery Of Double Stranded RNA To a Target Cell. Dr. Pachuk, the inventor said, The allowed claims cover transfecting double-stranded RNA into skin or muscle cells under conditions...

Glenmark Pharmaceuticals to Respond to Patent Row With Merck & Co., Inc. Next Month

Mon, 15 Apr 2013 12:00:00 AM GMT

The Delhi High Court on Friday sought response of Glenmark Pharmaceuticals on US drug major Merck Sharp and Dohme's appeal against the single judge bench order refusing to restrain the Indian firm from manufacturing and selling anti-diabetes drugs Zita and Zita-Met. A bench of Justices S Ravindra Bhat and S K Mishra issued a notice to Glenmark and sought its reply by May 22 on the US firm's plea challenging...

Repros Therapeutics Inc. Reports Issuance of Two Additional U.S. Androxal® Patents

Wed, 10 Apr 2013 12:00:00 AM GMT

THE WOODLANDS, Texas, April 10, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. (Nasdaq:RPRX) announced two patents representing potentially large commercial indications for its drug Androxal have been issued. The two patents deal with the metabolic consequences of low testosterone and the positive outcomes associated with restoration of testicular function exhibited by Androxal. The 8,377,991 patent...

Nodality, Inc. Announces Expansion of Company's Patent Estate Covering Programs to Improve the Treatment of Patients With Severe Diseases in Immunology, Oncology, and Autoimmune Diseases

Wed, 10 Apr 2013 12:00:00 AM GMT

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nodality, Inc., a next-generation life sciences company partnering with leading firms to advance precision medicine, announced today the issuance by the United States Patent and Trademark Office (USPTO) of Patent Number 8,394,599, which broadly covers methods for applying the Companys Single Cell Network Profiling (SCNP) technology. SCNP provides the core...

PROLOR Biotech Receives Notice of Allowance For New U.S. Patent Covering Long-Acting Coagulation Factors VII and IX

Mon, 08 Apr 2013 12:00:00 AM GMT

NES-ZIONA, Israel, April 8, 2013 /PRNewswire/ -- PROLOR Biotech, Inc. (NYSE MKT: PBTH) today announced that it received a notice of allowance from the U.S. Patent and Trademark Office for a new patent application covering the company's proprietary long-acting CTP-enhanced coagulation factors for the treatment...

Acura Pharmaceuticals, Inc. Awarded U.S. Patent for Abuse Deterrent Drug Formulations

Fri, 05 Apr 2013 12:00:00 AM GMT

PALATINE, IL--(Marketwired - April 04, 2013) - Acura Pharmaceuticals, Inc. (NASDAQ: ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, today announced that the company...

Santaris Pharma A/S Release: Issues Inter Partes Reexamination Certificate of Key LNA Patent

Fri, 05 Apr 2013 12:00:00 AM GMT

HOERSHOLM, Denmark and SAN DIEGO, April 5, 2013 /PRNewswire/ -- Santaris Pharma A/S, a clinical-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, today announced that the USPTO issued an Inter Partes Reexamination Certificate for U.S. Pat. No. 6,770,748 (the '748 patent) on

Antares Pharma, Inc. Announces Notice of Allowance for New Patent on VIBEX™ QuickShot Device

Fri, 05 Apr 2013 12:00:00 AM GMT

EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Allowance from the U.S. Patent Trade Office (USPTO) on a patent application for the VIBEX QuickShot (QS) device, the latest advancement in its proprietary line of VIBEX auto-injector systems. Paul K. Wotton, Ph.D., President and Chief Executive Officer, stated, The size and scope of...

NeuralStem Inc. Receives Notice of Allowance of Patent Covering Use of Stem Cells to Treat Amyotrophic Lateral Sclerosis

Fri, 05 Apr 2013 12:00:00 AM GMT

ROCKVILLE, Md., April 5, 2013 /PRNewswire/ -- Neuralstem, Inc. (NYSE MKT: CUR) announced today that it received a notice of allowance for patent application 12/404,841. This patent covers methods for treating amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) with expanded...

VolitionRX Files Two Patent Applications

Thu, 04 Apr 2013 12:00:00 AM GMT

NAMUR, Belgium, April 4, 2013 /PRNewswire/ -- VolitionRx Limited (OTC: VNRX), a life sciences company focused on developing blood-based diagnostic tests, announces that it has filed two new patent applications. The first patent application is an extension to the Nucleosomics

Synthetic Biologics, Inc. Announces Issuance of U.S. Patent Covering Combination of Estriol and Copaxone® for Multiple Sclerosis

Thu, 04 Apr 2013 12:00:00 AM GMT

ROCKVILLE, Md., April 4, 2013 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of synthetic biologics and innovative medicines for serious infections and diseases, announced today that the U.S. Patent & Trademark Office has issued U.S. Patent No. 8,372...

22nd Century Group, Inc. Announces U.S. Patent Issues for MPO Nicotine Biosynthesis Gene

Wed, 03 Apr 2013 12:00:00 AM GMT

CLARENCE, N.Y.--(BUSINESS WIRE)--22nd Century Group, Inc. (OTCBB: XXII), a company that has developed groundbreaking technology for tobacco harm reduction products, today announced that the United States Patent and Trademark Office (US PTO) has issued Patent No. 8,410,341 for the N-methylputrescine oxidase (MPO) gene technology. MPO is essential for production of nicotine in the tobacco plant. As previously...

Islet Sciences Receives Notice of Claims Allowance for U.S. Patent Application for New Medications for Treating Diabetes and other Serious Inflammatory Disorders

Wed, 03 Apr 2013 12:00:00 AM GMT

NEW YORK--(BUSINESS WIRE)--Islet Sciences, Inc., (OTC.BB: ISLT) a biotechnology company engaged in the research, development and commercialization of patented technologies for people with diabetes, announced today the receipt of a Notice of Claims Allowance for its U.S. Patent Application No. 12/036,646. The title of the invention is Lisofylline Analogs and Methods for Use.

Oramed Pharmaceuticals Inc. Granted Japanese Patent for Its Core Technology in Oral Delivery of Proteins

Wed, 03 Apr 2013 12:00:00 AM GMT

JERUSALEM, April 3, 2013 /PRNewswire/ --Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a developerof oral drug delivery systems, announced today that it has received approval fora key patent by the Japanese Patent Office. The patent, titled "Methods andCompositions for Oral Administrations of Proteins," covers a core concept of thecompany's technology. The patent has...

KemPharm, Inc. Receives Notice of Allowance for Novel Pain Drug Candidate, KP201

Wed, 03 Apr 2013 12:00:00 AM GMT

NORTH LIBERTY, Iowa, April 3, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, announced today that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for...

AstraZeneca PLC Suffers Fresh Drug Patent Setback in U.S.

Tue, 02 Apr 2013 12:00:00 AM GMT

AstraZeneca has suffered a fresh patent setback with a U.S. court decision that a patent protecting its Pulmicort Repsules asthma treatment is invalid, clearing the way for a generic copy from Actavis. The ruling comes as AstraZeneca is already facing a big fall in sales due to patent expiries on other medicines, prompting a $2.3 billion restructuring plan and further job losses announced by new CEO...

Zalicus Inc. Granted Key Formulation Patent for Z160

Tue, 02 Apr 2013 12:00:00 AM GMT

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zalicus Inc. (Nasdaq Global Market: ZLCS), a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, today announced that it has been granted a patent by the U.S. Patent and Trademark office (USPTO) covering novel formulations of its product candidate Z160. United States patent number 8,409,560, entitled Solid Dispersion...

Entia Biosciences Receives Notices of Allowance for Its Ergothioneine and Genetic Transporter Patents from the United States, Canada, and Israel

Tue, 02 Apr 2013 12:00:00 AM GMT

SHERWOOD, Ore., April 2, 2013 /PRNewswire/ -- Entia Biosciences (OTCQB: ERGO), a food science biotechnology company and emerging leader in the field of Nutrigenomics, has now received three Patent Notices of Allowance covering the use of Ergothioneine and its genetic transporter in the treatment of a wide variety...

Lithera Receives Patent From the Protecting Methods of Use and Formulations for LIPO-202

Tue, 02 Apr 2013 12:00:00 AM GMT

SAN DIEGO, April 2, 2013 /PRNewswire/ -- Lithera, Inc., a clinical stage pharmaceutical company focused on lifestyle and medical indications in aesthetic medicine and ophthalmology, today announced significant advances in the patent estate covering LIPO-202 (Salmeterol Xinafoate for Injection), the company's lead...

Novartis AG Loses Cancer Drug Glivec Patent Case

Mon, 01 Apr 2013 12:00:00 AM GMT

India's top court dismissed Swiss drugmaker Novartis AG's attempt to win patent protection for its cancer drug Glivec, a blow to Western pharmaceutical firms targeting India to drive sales and a victory for local makers of cheap generics. The decision sets a benchmark for intellectual property cases in India, where many patented drugs are unaffordable for most of its 1.2 billion people, and does not...

Cytori Therapeutics, Inc. Patents Method of Treating Renal Diseases Using Adipose-Derived Regenerative Cells

Thu, 28 Mar 2013 12:00:00 AM GMT

SAN DIEGO--(BUSINESS WIRE)--Cytori Therapeutics (NASDAQ: CYTX) received US Patent No. 8,404,229 (the 229 patent) for methods of treating renal diseases using adipose-derived regenerative cells (ADRCs). The 229 patent covers treatment of a broad range of renal disorders, including acute kidney disease (AKD) and chronic kidney disease (CKD). The 229 patent also covers multiple means of delivering...

Nutra Pharma Corp. Patent and Trademarks Published in India

Mon, 25 Mar 2013 12:00:00 AM GMT

CORAL SPRINGS, Fla., March 25, 2013 /PRNewswire/ -- Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that it has received notification that their...

Lpath, Inc. Granted Key European and U.S. Patents Related to Anti-Cancer Drug Program, ASONEP

Fri, 22 Mar 2013 12:00:00 AM GMT

SAN DIEGO, CA--(Marketwire - March 22, 2013) - Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the European Patent Office (EPO) and the U.S. Patent and Trademark Office (USPTO) that the company has been issued three key patents...

Epizyme Granted First Patent Covering Personalized Therapeutic Drug Candidate E7438

Fri, 22 Mar 2013 12:00:00 AM GMT

CAMBRIDGE, Mass., March 22, 2013 /PRNewswire-USNewswire/ -- Epizyme, Inc., a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today that it has received a Notice...

European Patent Office to Grant Patent for Macrocure's CureXcell®

Thu, 21 Mar 2013 12:00:00 AM GMT

PETACH TIKVA, Israel March 14, 2013 Macrocure (www.macrocure.com), a biotechnology company developing advanced cell therapy products, announced today that the European Patent Office (EPO) intends to grant a European patent covering Marcocures flagship product, CureXcell. The patent will be officially granted under an application titled Activate Leukocyte Composition and will provide patent...

StemCells Inc. Expands Patent Portfolio

Wed, 20 Mar 2013 12:00:00 AM GMT

NEWARK, Calif., March 20, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM) today announced that it has acquired from NsGene A/S, a privately held Danish biotechnology company, a patent family claiming GFAP Nestin cells, including U.S. Patent Nos. 6,878,543 and 7,303,912 and European patent application 00973148. GFAP and Nestin are proteins that are co-expressed by certain key cells found in...

Biogen Idec, Inc. (Massachusetts) Release: U.S. Patent Office Grants Patent Claiming Dosing Regimen for TECFIDERA™ (Dimethyl Fumarate)

Wed, 20 Mar 2013 12:00:00 AM GMT

WESTON, Mass.--(BUSINESS WIRE)--Biogen Idec (NASDAQ: BIIB) today announced that the U.S. Patent and Trademark Office (USPTO) has granted U.S. Patent No. 8,399,514, which offers additional protection for TECFIDERA (dimethyl fumarate), the companys oral therapeutic candidate for the treatment of multiple sclerosis (MS). The patent, which will expire in 2028, covers the dosing regimen of daily administration...

Palatin Technologies Announces Notification of Patent Allowance on Melanocortin Receptor-1 Specific Peptides

Tue, 19 Mar 2013 12:00:00 AM GMT

CRANBURY, N.J., March 19, 2013 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that the United States...

Dicerna Pharmaceuticals Announces Patent Issuance for DsiRNAs Directed at the KRAS Gene, a Key Cancer Regulator

Tue, 19 Mar 2013 12:00:00 AM GMT

WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (Dicerna), a second generation RNA interference (RNAi) company developing novel therapeutics utilizing its proprietary Dicer Substrate Technology and Dicer Substrate siRNA (DsiRNA) molecules, today announced that the United States Patent and Trademark Office (USPTO) has issued patent claims specific to double-stranded RNAs directed against...